Korro Bio, Inc. business relationships
Companies named in Korro Bio, Inc.’s 10-K filed 2026-03-12, and public companies whose annual reports name Korro Bio, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.6 / 10
- AI naming
- 2 / 100 Top 5% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Named in Korro Bio, Inc.’s annual report 3
“The Company also agreed to promptly wind-down its research and development activities in connection with the license agreement and Novo Nordisk agreed to reimburse the Company for certain wind-down costs associated with the hold period.” SEC filing
“In November 2025, we agreed to a 12 month pause on our collaboration with Novo Nordisk.” SEC filing
“In March 2023, Legacy Korro entered into a collaboration and license agreement (the "Genevant Agreement") with Genevant Sciences GmbH ("Genevant").” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.